Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME.
Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5.
Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa.
Hirami Y, Mandai M, Sugita S, Maeda A, Maeda T, Yamamoto M, Uyama H, Yokota S, Fujihara M, Igeta M, Daimon T, Fujita K, Ito T, Shibatani N, Morinaga C, Hayama T, Nakamura A, Ueyama K, Ono K, Ohara H, Fujiwara M, Yamasaki S, Watari K, Bando K, Kawabe K, Ikeda A, Kimura T, Kuwahara A, Takahashi M, Kurimoto Y.
Cell Stem Cell. 2023 Dec 7;30(12):1585-1596.e6. doi: 10.1016/j.stem.2023.11.004.
Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies.
Català-Mora J, Santamaría Álvarez JF, Kyriakou D, Alforja S, Barraso Rodrigo M, Blasco Palacio PB, Casaroli-Marano R, Cobos Martín E, Coco Martín RM, Esmerado C, García Tirado A, García P, Gómez-Benlloch A, Rodríguez Fernández CA, Vilaplana Mira F.
Arch Soc Esp Oftalmol (Engl Ed). 2024 Feb;99(2):67-81. doi: 10.1016/j.oftale.2023.11.001. Epub 2023 Nov 7.
CRB1-associated retinal degeneration is dependent on bacterial translocation from the gut.
Peng S, Li JJ, Song W, Li Y, Zeng L, Liang Q, Wen X, Shang H, Liu K, Peng P, Xue W, Zou B, Yang L, Liang J, Zhang Z, Guo S, Chen T, Li W, Jin M, Xing XB, Wan P, Liu C, Lin H, Wei H, Lee RWJ, Zhang F, Wei L.
Cell. 2024 Mar 14;187(6):1387-1401.e13. doi: 10.1016/j.cell.2024.01.040. Epub 2024 Feb 26.
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.
Michaelides M, Besirli CG, Yang Y, DE Guimaraes TAC, Wong SC, Huckfeldt RM, Comander JI, Sahel JA, Shah SM, Tee JJL, Kumaran N, Georgiadis A, Minnick P, Zeldin R, Naylor S, Xu J, Clark M, Anglade E, Wong P, Fleck PR, Fung A, Peluso C, Kalitzeos A, Georgiou M, Ripamonti C, Smith AJ, Ali RR, Forbes A, Bainbridge J.
Am J Ophthalmol. 2024 Nov;267:122-134. doi: 10.1016/j.ajo.2024.05.034. Epub 2024 Jun 12.
Etiology of Retinitis Pigmentosa.
Breazzano MP, Grewal MR, Tsang SH, Chen RWS.
Methods Mol Biol. 2023;2560:15-30. doi: 10.1007/978-1-0716-2651-1_2.
Tocilizumab for cystoid macular edema secondary to retinitis pigmentosa.
Abramowicz S, Kamgang Semeu P, Nubourgh I, Postelmans L, Willermain F.
J Ophthalmic Inflamm Infect. 2024 Sep 30;14(1):47. doi: 10.1186/s12348-024-00430-0.
Retinal vasoproliferative tumour secondary to retinitis pigmentosa sine pigmento.
Bromeo AJ, Lerit SJ, Veloso A, Mercado GJ.
BMJ Case Rep. 2021 May 19;14(5):e240878. doi: 10.1136/bcr-2020-240878.
Application of intravitreal aflibercept to treat bilateral exudative retinal detachment secondary to retinitis pigmentosa: Case report and review of literature.
Kao CC, Chen KJ, Cheng KC.
Medicine (Baltimore). 2023 Dec 22;102(51):e36589. doi: 10.1097/MD.0000000000036589.
Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial.
Chen Y, Pan Y, Xie Y, Shi Y, Lu Y, Xia Y, Su W, Chen X, Li Z, Wang M, Miao S, Yang Y, Jin C, Luo G, Long S, Xiao H, Huang C, Zhang J, Liang D.
Signal Transduct Target Ther. 2024 Dec 4;9(1):339. doi: 10.1038/s41392-024-02037-2.
